184 related articles for article (PubMed ID: 9850457)
1. Immunosuppressive therapy with microemulsion cyclosporine A shortens the hospitalization of pediatric liver transplant recipients.
Arumugam R; Soriano HE; Scheimann AO; Reid BS; Gopalakrishna GS; Barakat O; Ozaki CF; Wood PR
Clin Transplant; 1998 Dec; 12(6):588-92. PubMed ID: 9850457
[TBL] [Abstract][Full Text] [Related]
2. A pharmacoeconomic analysis of Neoral without intravenous cyclosporine in liver transplantation in Canada.
Hemming AW; Cattral MS; Greig PD; Meisner J; Turcotte L; Lilly LB; Levy GA
Clin Transplant; 1998 Oct; 12(5):425-9. PubMed ID: 9787952
[TBL] [Abstract][Full Text] [Related]
3. [A comparative randomized prospective multicenter study of Sandimmune vs Neoral in liver transplantation].
Roy A; Grant DR; Kneteman NM; Tchervenkov JI; Levy GA; Tan A; Hendricks L
Ann Chir; 1998; 52(8):716-21. PubMed ID: 9846420
[TBL] [Abstract][Full Text] [Related]
4. Comparison of pharmacokinetics of Neoral and Sandimmune in stable pediatric liver transplant recipients.
van Mourik ID; Thomson M; Kelly DA
Liver Transpl Surg; 1999 Mar; 5(2):107-11. PubMed ID: 10071349
[TBL] [Abstract][Full Text] [Related]
5. Economic analysis of Neoral in de novo renal transplant patients in Canada.
Kingma I; Ludwin D; Dandavino R; Wolff JL; Loertscher R; Beauregard-Zollinger L; Bacquet P; Boucher S; Rivière M
Clin Transplant; 1997 Feb; 11(1):42-8. PubMed ID: 9067694
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetic, hemodynamic, and metabolic effects of cyclosporine sandimmune versus the microemulsion neoral in heart transplant recipients.
White M; Pelletier GB; Tan A; Jesina C; Carrier M
J Heart Lung Transplant; 1997 Aug; 16(8):787-94. PubMed ID: 9286770
[TBL] [Abstract][Full Text] [Related]
7. Comparison of generic cyclosporine microemulsion versus neoral in de novo renal transplant recipients managed by 2-hour postdose monitoring.
Sharma A; Shekhar C; Heer M; Minz M
Transplant Proc; 2006 Sep; 38(7):2051-3. PubMed ID: 16979996
[TBL] [Abstract][Full Text] [Related]
8. Impact of late conversion from C0 to C2 monitoring of microemulsified cyclosporine in pediatric living donor liver transplant recipients.
Takatsuki M; Chen CL; Chen YS; Wang CC; Lin CC; Yang CH; Yong CC; Liu YW
Clin Transplant; 2004 Dec; 18(6):694-9. PubMed ID: 15516246
[TBL] [Abstract][Full Text] [Related]
9. Microemulsion technology in the reformulation of cyclosporine: the reason behind the pharmacokinetic properties of Neoral.
Ritschel WA
Clin Transplant; 1996 Aug; 10(4):364-73. PubMed ID: 8884110
[TBL] [Abstract][Full Text] [Related]
10. Cyclosporin A (Neoral) in pediatric organ transplantation. Neoral Pediatric Study Group.
Hoyer PF
Pediatr Transplant; 1998 Feb; 2(1):35-9. PubMed ID: 10084758
[TBL] [Abstract][Full Text] [Related]
11. Conversion from tacrolimus to cyclosporine microemulsion therapy in liver transplant recipients.
Ogino S; Hashikura Y; Katsuyama Y; Ikegami T; Nakazawa Y; Urata K; Terada M; Miyagawa S; Kawasaki S
Transplant Proc; 2004 Mar; 36(2 Suppl):299S-301S. PubMed ID: 15041357
[TBL] [Abstract][Full Text] [Related]
12. [Conversion from +Sandimmune to Neoral in kidney transplant recipients treated with cyclosporine and ketoconazole].
Videla C; Vega J; Borja H; Gatica A; Clavero R; Aldunate T
Rev Med Chil; 1997 Apr; 125(4):438-45. PubMed ID: 9460285
[TBL] [Abstract][Full Text] [Related]
13. Conversion from Sandimmune to Neoral and induction therapy with Neoral in pediatric renal transplant recipients.
Hoyer PF; Boekenkamp A; Vester U; Offner G; Brodehl J
Transplant Proc; 1996 Aug; 28(4):2259-61. PubMed ID: 8769218
[No Abstract] [Full Text] [Related]
14. Randomized, double-blind, one-year study of the safety and tolerability of cyclosporine microemulsion compared with conventional cyclosporine in renal transplant patients. International Sandimmun Neoral Study Group.
Frei UA; Neumayer HH; Buchholz B; Niese D; Mueller EA
Transplantation; 1998 Jun; 65(11):1455-60. PubMed ID: 9645802
[TBL] [Abstract][Full Text] [Related]
15. [A single-center controlled clinical study with Sandimmune Neoral after kidney transplantation].
Matl I; Vítko S; Lácha J; Horcicková M; Nosková L; Símová M; Táborský P; Viklický O; Hulínský V; Lánská V
Vnitr Lek; 1997 Nov; 43(11):703-6. PubMed ID: 9650498
[TBL] [Abstract][Full Text] [Related]
16. Experience with neoral versus sandimmune in primary liver transplant recipients.
Pinson CW; Chapman WC; Wright JK; Hunter EB; Awad JA; Raiford DS; Payne JL; Geevarghese S; Blair TK; Van Buren DH
Transpl Int; 1998; 11 Suppl 1():S278-83. PubMed ID: 9664997
[TBL] [Abstract][Full Text] [Related]
17. An open-label study of the safety and tolerability of converting stable liver transplant recipients to neoral.
Pasha TM; Wiesner RH; Dahlke LM; Porayko MK; Krom RA
Liver Transpl Surg; 1998 Sep; 4(5):410-5. PubMed ID: 9724479
[TBL] [Abstract][Full Text] [Related]
18. Randomized, trough blood cyclosporine concentration-controlled trial to compare the pharmacodynamics of Sandimmune and Neoral in de novo lung transplant recipients.
Trull A; Steel L; Sharples L; Stewart S; Parameshwar J; McNeil K; Wallwork J
Ther Drug Monit; 1999 Feb; 21(1):17-26. PubMed ID: 10051050
[TBL] [Abstract][Full Text] [Related]
19. Benefits of pre-emptive dose reduction for Sandimmune to Neoral conversion in stable renal transplant recipients.
Hricik DE; Dixit A; Knauss TC; Donley V; Bartucci MR; Schulak JA
Clin Transplant; 1998 Dec; 12(6):575-8. PubMed ID: 9850454
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics of cyclosporine in heart transplant recipients receiving metabolic inhibitors.
Akhlaghi F; Keogh AM; McLachlan AJ; Kaan A
J Heart Lung Transplant; 2001 Apr; 20(4):431-8. PubMed ID: 11295581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
